Cyclosporin A analogues: Recent advances

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 9, 2003, Pages 1327-1332

  Lazarova, Tsvetelina ^a   Weng, Zhigang ^b  

^a SUNTORY LTD   (Japan)

^b Infinity Pharmaceuticals Inc   (United States)

Author keywords

Calcineurin; Cyclophilin A (CyP); Cyclosporin A (CsA); Cyclosporin A analogues; Immunosuppression; Nuclear factor of activated T cells (NFAT)

Indexed keywords

ANTIRETROVIRUS AGENT; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOPHILIN A; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE; EP 314; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ASTHMA; ATOPIC DERMATITIS; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG USE; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORGAN TRANSPLANTATION; PNEUMONIA; PSORIASIS; RETROVIRUS; RETROVIRUS INFECTION; RHEUMATOID ARTHRITIS; SKIN DISEASE; X RAY CRYSTALLOGRAPHY;

EID: 0141517204     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.9.1327     Document Type: Editorial

References (58)

1. DREYFUSS M, HARRI E, HOFMANN H et al.: Cyclosporin A and C. New metabolites from Trichoderma polysporum. Eur. J. Appl. Microbiol. (1976) 3:125-133.
2. WENGER RM: Synthesis of cyclosporin. Total synthesis of cyclosporin A and cyclosporin H, two fungal metabolites isolated from the species Tolypocladium inflatum. Helv. Chim. Acta (1984) 67:502-525.
3. SPITZFADEN C, BRAUN W, WIDER G et al.: Determination of the NMR solution structure of the cyclophilin A-cyclosporin A complex. J. Biomol. NMR (1994) 4:463-482.
4. MIKOL V, KALLEN J, AFLUENGE G et al.: X-ray structure of a monomeric cyclophilin A-cyclosporin A complex at 2.1.ANG resolution. J. Mol. Biol. (1993) 234:1119-1130.
5. MATOUSCHEK A, ROSPERT S, SCHMID K et al.: Cyclophilin catalyzes protein folding in yeast mitochondria. Proc. Natl. Acad. Sci. USA (1996) 92:6319-6323.
6. RAO A, LUO C, HOGAN PG: Transcription factors of the NFAT family: regulation and function. Ann. Rev. Immunol. (1997) 15:707-747.
7. HUAI Q, KIM HY, LIU Y et al.: Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin drug complexes. Proc. Natl. Acad. Sci. USA (2002) 99:12037-12042.
8. JIN L, HARRISON SC: Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc. Natl. Acad. Sci. USA (2002) 99(21):13522-13526.
9. LOH C, KAREN TY, SHAW JC et al.: Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J. Biol. Chem. (1996) 271:10884-10891.
10. SHAW KT, HO AM, RAGHAVAN A et al.: Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc. Natl. Acad. Sci. USA (1995) 92:11205-11209.
11. KIANI A, RAO A, ARAMBURU J: Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity (2000) 12(4):359-372.
12. HO S, CLIPSTONE N, TIMMERMANN L et al.: The mechanism of action of cyclosporin A and FK-506. Clin. Immunol. Immunopathol. (1996) 80:S40-S45.
13. FAULDS D, GOA KL, BENFILED P: Cyclosporin, a review of its pharmacadynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drug (1993) 45:953-995.
14. RUSH DN: Cyclosporine toxicity to organs other than the kidney. Clin. Biochem. (1991) 24:101-105.
15. KEOWN PA, STILLER CR, WALLACE AC: Effect of cyclosporine on the kidney. J. Pediatr. (1987) 111:1029-1033.
16. REMUZZI G, BERTANI T: Renal vascular and thrombotic effects of cyclosporine. Am. J. Kidney Dis. (1989) 13:261-272.
17. KUMAR KV, NAIDU MU, SHIFOW AA et al.: Melatonin: an antioxidant protects against cyclosporine-induced nephrotoxicity. Transplantation (1999) 67:1065-1068.
18. ZHONG Z, CONNOR HD, YIN M et al.: Viral delivery of superoxide dismutase gene reduces cyclosporine A-induced nephrotoxicity. Kidney Int. (2001) 59:1397-1404.
19. ZHONG Z, CONNOR HD, YIN M et al.: Dietary glycine and renal denervation prevents cyclosporin A-induced hydroxyl radical production in rat kidney. Mol. Pharmacol. (1999) 56:455-463.
20. PALLER MS, WEBER K, PATTEN M: Nitric oxide-mediated renal epithelial cell injury during hypoxia and reoxygenation. Ren. Fail. (1998) 20:459-469.
21. YU L, GENGARO PE, NIEDERBERGER M et al.: Nitric oxide: a mediator in rat tubular hypoxia/reoxygenation injury. Proc. Natl. Acad. Sci. USA (1994) 91:691-1695.
22. HORTELANO S, CASTILLA M, TORRES AM et al.: Potentiation by nitric oxide of cyclosporin A and FK-506-induced apoptosis in renal proximal tubule cells. J. Am. Soc. Nephrol. (2000) 11:2315-2323.
23. SHEIK-HAMAD D, NADKARNI V, CHOI YJ et al.: Cyclosporine A inhibits the adaptive responses to hypertonicity: a potential mechanism of nephrotoxicity. J. Am. Soc. Nephrol. (2001) 12:2732-2741.
24. AMERICAN HOSPITAL FORMULARY SERVICE: AHFS Drug Information 91 (33rd Edn). American Society of Hospital Pharmacists, Bethesda, MD, USA (1991).
25. LYSON T, ERMEL LD, BELSHAW PJ: Cyclosporine- and FK-506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T cell signaling. Circ. Res. (1993) 73:596-602.
26. WENGER RM: Pharmacology of cyclosporin (sandimmune). II. Chemistry. Pharm. Rev. (1989) 41:243-247.
27. ANGELL YM, THOMAS TL, FLENKLE GR et al.: Solid phase synthesis of cyclosporin peptides. J. Am. Chem. Soc. (1995) 117:7279-7280.
28. RAMAN P, STOKES S, ANGELL YM, FLENTKE GR, RICH DH: Methods to circumvent a difficult coupling in the solid-phase synthesis of cyclosporin analogs. J. Org. Chem. (1998) 63(17):5734-5735.
29. RICH DH, SUN CQ, GUILLIAUME D et al.: Synthesis, biological activity and conformational analysis of (2S, 3R, 4S)-McBmt-cyclosporin, a novel 1-position epimer of cyclosporin A. J. Med. Chem. (1989) 32:1982-1987.
30. TRABER R, HOFMANN H, KOBEL H: Cyclosporins - new analogs by precursor-directed biosynthesis. J. Antibiotics (1989) 42:591-597.
31. LAWEN A, TRABER R, GEYL D et al.: Cell-free biosynthesis of new cyclosporins. J. Antibiotics (1989) 42:1204-1206.
32. LOOR F, TIBERGHIEN F, WENANDY T et al.: Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. J. Med. Chem. (2002) 45:4598-4612.
33. AEBI AD, DEYO DT, SUN SQ et al.: Cyclosporin A modified in the 1-position. J. Med. Chem. (1990) 33:999-1009.
34. PAPRICA PA, MARGARITAS A, PETERSEN NO: Preparation of novel cyclosporin A derivatives. Bioconjugate Chem. (1992) 3:32-36.
35. EBERLE MK, JUTZI-EME AM, NUNINGER F: Modifications of the MeBmt side chain of cyclosporin A. Bioorg. Med. Chem. Lett. (1995) 5:1725-1728.
36. EBERLE MK, NUNINGER F: Preparation of functionalized ethers of cyclosporin A. Tetrahedron Lett. (1994) 35:6477-6480.
37. EBERLE MK, NUNINGER F, WEBER HP: Preparation of sulfhydryl cyclosporin A. J. Org. Chem. (1995) 60:2610-2612.
38. EBERLE MK, NUNINGER F: Synthesis of the main metabolite (OL-17) of cyclosporin A. J. Org. Chem. (1992) 57:2689-2691.
39. PARK SB, MEIER GP: A semisynthetic approach to olefinic analogs of amino acid one (MeBMT) in cyclosporin A. Tetrahedron Lett. (1989) 30:42154218.
40. SMULIK JA, DIVER ST, PAN F et al.: Synthesis of cyclosporin A-derived affinity reagents by olefin metathesis. Org. Lett. (2002) 4(12):2051-2054.
41. LAZAROVA T, CHEN JS, HAMMAN B et al.: Synthesis and biological evaluation of novel cyclosporin A analogues: potential soft drugs for the treatment of autoimmune diseases. J. Med. Chem. (2003) 46:674-676.
42. CHEN JS, LAZAROVA T, HAMMAN B et al.: Synthesis and biological evaluation of novel cyclosporin A derivatives with potentially improved therapeutic index. 225th National Meeting of the Am. Chem. Soc. New Orleans, LA, USA (March 2003) (Poster presentation).
43. SEEBACH D, BECK AK, BOSSLER HG et al.: Modification of cyclosporin A (CS): generation of an enolate at the sarcosine residue and reactions with electrophiles. Helv. Chim. Acta (1993) 76:1564-1590.
44. PAPAGEORGIOU C, KALLEN J, FRANCA J et al.: Conformational control of cyclosporin through substitution of the N-5 position. A new class of cyclosporin antagonists. Bioorg. Med. Chem. (1997) 5:187-192.
45. EBERLE MK, JUTZI-EME AM, NUNINGER F: Cyclosporin A; regioselective ring opening and fragmentation reactions via thioamides. A route to semi-synthetic cyclosporins. J. Org. Chem. (1994) 59:7249-7258.
46. DUNN CJ, WAGSTAFF AJ, PERRY CM et al.: Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) in organ transplantation. Drugs (2001) 61:1957-2016.
47. ROTHBARD JB, GARLINGTON S, LIN Q et al.: Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. (2000) 6:1253-1257.
48. ROTHBARD JB, KREIDER E, VANDEUSEN CL et al.: Arginine-rich molecular transporters for drug delivery: role of backbone spacing on cellular uptake. J. Med. Chem. (2002) 45(17):3612-3618.
49. LU ZR, GAO SQ, KOPECKOVA P et al.: Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers. Bioconjugate Chem. (2001) 12:129-133.
50. LU ZR, GAO SQ, KOPECKOVA P et al.: Synthesis of bioadhesive lectin-HMPA copolymer-cyclosporin conjugates. Bioconjugate Chem. (2000) 11:3-7.
51. QUESNIAUX VFJ, SCHREIER MH, WENGER RM, HIESTAND PC, HARDING MW, VAN REGENMORTEL MHV: Cyclophilin binds to the region of cyclosporine involved in its immunosuppressant activity. Eur. J. Immunol. (1987) 17(9):1359-1365.
52. RIZZARDI GP, HARARI A, CAPILUPPI B et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest. (2002) 109:681-688.
53. CRON RQ: HIV-1, NFAT, and cyclosporin: immunosuppression for the immunosuppressed? DNA Cell Biol. (2001) 20:761-767.
54. STREBLOW DN, KITABWALLA M, MALKOVSKY M et al.: Cyclophilin A modulates processing of human immunodeficiency virus Type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology (1998) 245:197-202.
55. BRAATEN D, LUBAN J: Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. (2001) 20:1300-1309.
56. FURLANUT M, BARALDO M, GALLA F: Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis. Pharm. Res. (1996) 33:349-352.
57. CHRISTIANS U, SEWING KF: Alternative cyclosporine metabolic pathways and toxicity. Clin. Biochem. (1995) 28:547-559.
58. tx247. J. Rheum. (2002) 29(8):1646-1652.